InsidersTradesSigma
Follow the Intra-Cellular Therapies, Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Intra-Cellular Therapies, Inc. has logged 160 public disclosures. The latest transaction was filed on 2 April 2025 (Disposition). Among the most active insiders: Mates Sharon. The full history is openly available.
160
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€164m
29 ops.
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 2 April 2025
Declarations160 total
21,307 shares@ US$132.0043.1% of flowCommon StockSEC:0000950170-25-049646:0
52,811 shares@ US$132.0059.7% of flowCommon StockSEC:0000950170-25-049627:0
48,238 shares@ US$132.0060.4% of flowCommon StockSEC:0000950170-25-049596:0
42,913 shares@ US$132.0060.4% of flowCommon StockSEC:0000950170-25-049593:0
11,340 shares@ US$132.0055.3% of flowCommon StockSEC:0000950170-25-049636:0
131,512 shares@ US$132.0090.2% of flowCommon StockSEC:0000950170-25-049648:0
945,235 shares@ US$132.0092.8% of flowCommon StockSEC:0000950170-25-049595:0
1,567 shares@ US$132.00100.0% of flowCommon StockSEC:0000950170-25-049830:0
190,000 shares0Common StockSEC:0000950170-25-047937:0
13,133 sharesCommon StockSEC:0000950170-25-036591:0
13,133 sharesCommon StockSEC:0000950170-25-036594:0
40,712 sharesCommon StockSEC:0000950170-25-036593:0
13,133 sharesCommon StockSEC:0000950170-25-036592:0
8,742 sharesCommon StockSEC:0000950170-25-032585:0
8,742 sharesCommon StockSEC:0000950170-25-032584:0
34,969 sharesCommon StockSEC:0000950170-25-032587:0
12,239 sharesCommon StockSEC:0000950170-25-032586:0
7,009 shares@ US$63.794.4% of flowCommon StockSEC:0000950170-25-028030:0
11,017 shares0Common StockSEC:0000950170-25-013749:0
30,847 shares0Common StockSEC:0000950170-25-013765:0
11,017 shares0Common StockSEC:0000950170-25-013762:0
11,017 shares0Common StockSEC:0000950170-25-013763:0
215 shares@ US$83.520.1% of flowCommon StockSEC:0000950170-25-001440:0
51,000 shares@ US$12.730.5% of flowCommon StockSEC:0000950170-24-134240:0
22,869 shares@ US$23.948.6% of flowCommon StockSEC:0000950170-24-127275:0
25 of 160 declarations
关于 Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. 是一家在美国纳斯达克上市的美国生物制药公司，专注于中枢神经系统疾病，专门从事创新精神疾病疗法的发现、开发和商业化。公司总部位于新泽西州贝德明斯特。其科学根源与细胞内信号传导研究相关，其商业身份现已由其主要资产 CAPLYTA® (lumateperone) 确立。（[intracellulartherapies.com](https://www.intracellulartherapies.com/Contact-us/?utm_source=openai)） 公司目前的商业模式由 CAPLYTA 驱动，这是一种在美国获批用于成人精神分裂症和成人双相情感障碍的非典型抗精神病药物。此外，Intra-Cellular Therapies 已提交补充申请，用于重度抑郁症的辅助治疗，如果获批，这将显著扩大该产品的潜在市场。其 2024 年业绩显示出强劲的商业势头，CAPLYTA 的净产品销售额同比大幅增长，凸显了在高度专业化的治疗领域中市场渗透率的提高和有效的执行。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1567514/000119312525031355/d923815dex991.htm?utm_source=openai)） 从竞争角度来看，该公司在专业精神病学领域占据了一个有吸引力但竞争激烈的利基市场。其差异化来自于临床上已确立的主要产品和包括非 lumateperone 项目（如 ITI-1284、ITI-214 和 ITI-1500）的管线。这为公司带来了近期商业杠杆和长期管线选择权。在神经精神病学领域，耐受性、疗效和处方医生熟悉度至关重要，差异化的产品特性可能是一个重要的优势，但持续增长仍取决于适应症的扩展、医生的采用和支付方的准入。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1567514/000119312525031355/d923815dex991.htm?utm_source=openai)） 最近的里程碑对投资案例至关重要。FDA 接受了公司关于 CAPLYTA 在辅助 MDD 中的补充新药申请，而 2024 年的销售增长证实了该产品的商业轨迹。公司还扩大了销售力度，以支持潜在的更广泛上市。一项重大的公司发展是强生公司于 2025 年 4 月 2 日完成了对 Intra-Cellular Therapies 的收购，这实质性地改变了该资产的所有权和战略背景。对于投资者而言，现在的关键问题集中在 CAPLYTA 特许经营权的持续扩张、额外适应症的监管路径以及神经精神病学平台最终如何整合到全球制药产品组合中。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1567514/000119312525031355/d923815dex991.htm?utm_source=openai)）
